

6th International Conference and Exhibition on

Biosensors & Bioelectronics

September 22-23, 2016 Phoenix, USA

The NeXtStep in SPR based fragment screening

Eric L Reese

SensiQ Technologies Inc., USA

SensiQ's patented gradient injection methods provide KD's from single injections, allowing SensiQ instruments to eliminate secondary screens such as one competitor's "Affinity Screen". No other SPR providers have gradient injection technology. SensiQ Pioneer FE customers have demonstrated that a combination of excellent sensitivity, OneStep[®] gradient injections and the integrated Active Selection software provides superior results over other SPR suppliers. Now SensiQ has developed a new binding competition assay method for rapidly screening fragments, NeXtStep. Like OneStep[®], NeXtStep enables full kinetic analysis in single competition injection and competition is clearly seen as a lack of binding in the presence of the competitor. Taken together, OneStep[®] and NeXtStep enable straight forward fragment screening workflow optimization and thus a faster drug discovery process.

eric.reese@sensiqtech.com